Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.
Together, the two studies underscored the significance of precision medicine and equitable health-care access in enhancing outcomes for endometrial cancer.
DUO-E Trial
In the first study, researchers analyzed the results from the DUO-E trial—which evaluated the use of the immune checkpoint inhibitor durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without the PARP inhibitor olaparib in patients with mismatch repair–proficient endometrial cancer.
The researchers indicated that the combination of durvalumab and olaparib improved progression-free survival compared with chemotherapy alone, particularly among patients with specific biomarkers and those with detectable circulating tumor DNA.
Lead study author Kathleen Moore, MD, of the University of Oklahoma, and her colleagues highlighted the significance of biomarker-driven treatment approaches and suggested that identifying patients most likely to benefit from combination therapy could help tailor treatments and improve outcomes.
PUMBA Trial
In the second study, the multi-institutional PUMBA study, investigators examined racial disparities in the diagnosis of endometrial cancer.
The investigators observed that Black patients with postmenopausal bleeding were less likely to receive timely endometrial sampling following an abnormal transvaginal ultrasound, potentially leading to later-stage diagnoses.
Lead study author Angela Nolin, MD, of Duke University, and her colleagues emphasized the need to address racial disparities in endometrial cancer detection. Ensuring guideline-concordant care and improving follow-up after abnormal ultrasounds could significantly impact survival rates among Black patients.
Disclosure: For full disclosures of the study authors, visit sgo.org.
